New York Times business news - Nov 30



Nov 30 (Reuters) - The following are the top stories on the New York Times business pages. Reuters has not verified these stories and does not vouch for their accuracy.

- Eisai Co Ltd 4523.T and Biogen Inc BIIB.O released new data Tuesday evening, offering the first detailed look at the effects of the experimental Alzheimer's drug, lecanemab, suggesting that the treatment slowed cognitive decline for people in the early stages of the disease but also caused some patients to experience brain swelling or brain bleeding.

- Congressional leaders said on Tuesday that they would pass legislation to prevent a nationwide rail strike, agreeing with U.S. President Biden that a strike could shut down a critical piece of the economy and potentially inflame an inflation problem in the United States.

- The South Carolina Supreme Court on Tuesday ordered Mark Meadows, a White House chief of staff under former U.S. President Donald J. Trump, to testify in the criminal investigation into efforts by Mr. Trump and his allies to overturn his November 2020 election loss in Georgia. (Compiled by Bengaluru newsroom)

Disclaimer: The XM Group entities provide execution-only service and access to our Online Trading Facility, permitting a person to view and/or use the content available on or via the website, is not intended to change or expand on this, nor does it change or expand on this. Such access and use are always subject to: (i) Terms and Conditions; (ii) Risk Warnings; and (iii) Full Disclaimer. Such content is therefore provided as no more than general information. Particularly, please be aware that the contents of our Online Trading Facility are neither a solicitation, nor an offer to enter any transactions on the financial markets. Trading on any financial market involves a significant level of risk to your capital.

All material published on our Online Trading Facility is intended for educational/informational purposes only, and does not contain – nor should it be considered as containing – financial, investment tax or trading advice and recommendations; or a record of our trading prices; or an offer of, or solicitation for, a transaction in any financial instruments; or unsolicited financial promotions to you.

Any third-party content, as well as content prepared by XM, such as: opinions, news, research, analyses, prices and other information or links to third-party sites contained on this website are provided on an “as-is” basis, as general market commentary, and do not constitute investment advice. To the extent that any content is construed as investment research, you must note and accept that the content was not intended to and has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such, it would be considered as marketing communication under the relevant laws and regulations. Please ensure that you have read and understood our Notification on Non-Independent Investment. Research and Risk Warning concerning the foregoing information, which can be accessed here.

We are using cookies to give you the best experience on our website. Read more or change your cookie settings.

Risk Warning: Your capital is at risk. Leveraged products may not be suitable for everyone. Please consider our Risk Disclosure.